Monopar Therapeutics Inc. Operating Expenses
Monopar Therapeutics Inc. (MNPR) reported Operating Expenses of $6.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Monopar Therapeutics Inc. operating expenses for the quarter ending 2026-06-30 was $6.64M, a 105.44% increase year-over-year.
- Monopar Therapeutics Inc. operating expenses for the quarter ending 2026-03-31 was $5.23M, a 62.18% increase year-over-year.
- Monopar Therapeutics Inc. operating expenses for the quarter ending 2025-12-31 was $6.16M, a 44.42% decline year-over-year.
- Monopar Therapeutics Inc. operating expenses for the quarter ending 2025-09-30 was $4.09M, a 159.89% increase year-over-year.
- Monopar Therapeutics Inc. operating expenses for fiscal 2025 was $16.70M, a 3.36% increase from fiscal 2024.
- Monopar Therapeutics Inc. operating expenses for fiscal 2024 was $16.16M, a 83.01% increase from fiscal 2023.
- Monopar Therapeutics Inc. operating expenses for fiscal 2023 was $8.83M, a 16.19% decline from fiscal 2022.
- Monopar Therapeutics Inc. operating expenses for fiscal 2022 was $10.54M, a 15.44% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6.64M 10-Q · filed 2026-08-12 | $11.87M 10-Q · filed 2026-08-12 | $18.03M derived: sum of 3 quarters · filed 2026-08-12 | $22.12M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $5.23M 10-Q · filed 2026-05-14 | $11.38M derived: sum of 2 quarters · filed 2026-05-14 | $15.47M derived: sum of 3 quarters · filed 2026-05-14 | $18.71M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | $6.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $10.25M derived: sum of 2 quarters · filed 2026-03-27 | $13.48M derived: sum of 3 quarters · filed 2026-08-12 | $16.70M 10-K · filed 2026-03-27 | ||
| 2025-09-30 | $4.09M 10-Q · filed 2025-11-13 | $7.33M derived: sum of 2 quarters · filed 2026-08-12 | $10.55M 10-Q · filed 2025-11-13 | $21.62M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $3.23M 10-Q · filed 2026-08-12 | $6.46M 10-Q · filed 2026-08-12 | $17.53M derived: sum of 3 quarters · filed 2026-08-12 | $19.11M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $3.22M 10-Q · filed 2026-05-14 | $14.30M derived: sum of 2 quarters · filed 2026-05-14 | $15.87M derived: sum of 3 quarters · filed 2026-05-14 | $17.66M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $11.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $12.65M derived: sum of 2 quarters · filed 2026-03-27 | $14.44M derived: sum of 3 quarters · filed 2026-03-27 | $16.16M 10-K · filed 2026-03-27 | ||
| 2024-09-30 | $1.57M 10-Q · filed 2025-11-13 | $3.36M derived: sum of 2 quarters · filed 2025-11-13 | $5.09M 10-Q · filed 2025-11-13 | $7.00M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $1.79M 10-Q · filed 2025-08-12 | $3.51M 10-Q · filed 2025-08-12 | $5.42M derived: sum of 3 quarters · filed 2025-08-12 | $7.49M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | $1.72M 10-Q · filed 2025-05-13 | $3.64M derived: sum of 2 quarters · filed 2025-05-13 | $5.70M derived: sum of 3 quarters · filed 2025-05-13 | $8.03M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $3.98M derived: sum of 2 quarters · filed 2025-03-31 | $6.31M derived: sum of 3 quarters · filed 2025-03-31 | $8.83M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $2.07M 10-Q · filed 2024-11-08 | $4.39M derived: sum of 2 quarters · filed 2024-11-08 | $6.92M 10-Q · filed 2024-11-08 | $9.83M derived: sum of 4 quarters · filed 2024-11-08 | ||
| 2023-06-30 | $2.33M 10-Q · filed 2024-08-09 | $4.85M 10-Q · filed 2024-08-09 | $7.76M derived: sum of 3 quarters · filed 2024-08-09 | $10.17M derived: sum of 4 quarters · filed 2024-08-09 | ||
| 2023-03-31 | $2.53M 10-Q · filed 2024-05-09 | $5.43M derived: sum of 2 quarters · filed 2024-05-09 | $7.84M derived: sum of 3 quarters · filed 2024-05-09 | $10.60M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $5.32M derived: sum of 2 quarters · filed 2024-03-28 | $8.08M derived: sum of 3 quarters · filed 2024-03-28 | $10.54M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | $2.41M 10-Q · filed 2023-11-09 | $5.17M derived: sum of 2 quarters · filed 2023-11-09 | $7.63M 10-Q · filed 2023-11-09 | $10.31M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $2.76M 10-Q · filed 2023-08-10 | $5.22M 10-Q · filed 2023-08-10 | $7.90M derived: sum of 3 quarters · filed 2023-08-10 | $10.36M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $2.46M 10-Q · filed 2023-05-11 | $5.14M derived: sum of 2 quarters · filed 2023-05-11 | $7.60M derived: sum of 3 quarters · filed 2023-05-11 | $9.69M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $5.14M derived: sum of 2 quarters · filed 2023-03-23 | $7.23M derived: sum of 3 quarters · filed 2023-03-23 | $9.13M 10-K · filed 2023-03-23 | ||
| 2021-09-30 | $2.46M 10-Q · filed 2022-11-10 | $4.55M derived: sum of 2 quarters · filed 2022-11-10 | $6.45M 10-Q · filed 2022-11-10 | $8.71M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $2.09M 10-Q · filed 2022-08-11 | $3.99M 10-Q · filed 2022-08-11 | $6.25M derived: sum of 3 quarters · filed 2022-08-11 | $7.90M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $1.89M 10-Q · filed 2022-05-12 | $4.16M derived: sum of 2 quarters · filed 2022-05-12 | $5.80M derived: sum of 3 quarters · filed 2022-05-12 | $7.27M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $3.91M derived: sum of 2 quarters · filed 2022-03-24 | $5.37M derived: sum of 3 quarters · filed 2022-03-24 | $6.51M 10-K · filed 2022-03-24 | ||
| 2020-09-30 | $1.65M 10-Q · filed 2021-11-12 | $3.11M derived: sum of 2 quarters · filed 2021-11-12 | $4.25M 10-Q · filed 2021-11-12 | $5.47M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | $1.46M 10-Q · filed 2021-08-12 | $2.60M 10-Q · filed 2021-08-12 | $3.83M derived: sum of 3 quarters · filed 2021-08-12 | $4.58M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $1.14M 10-Q · filed 2021-05-13 | $2.36M derived: sum of 2 quarters · filed 2021-05-13 | $3.12M derived: sum of 3 quarters · filed 2021-05-13 | $4.05M derived: sum of 4 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.98M derived: sum of 2 quarters · filed 2021-03-25 | $2.92M derived: sum of 3 quarters · filed 2021-03-25 | $4.32M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $759.45K 10-Q · filed 2020-11-12 | $1.69M derived: sum of 2 quarters · filed 2020-11-12 | $3.10M 10-Q · filed 2020-11-12 | $4.03M derived: sum of 4 quarters · filed 2020-11-12 | ||
| 2019-06-30 | $932.11K 10-Q · filed 2020-08-06 | $2.34M 10-Q · filed 2020-08-06 | $3.27M derived: sum of 3 quarters · filed 2020-08-06 | $3.93M derived: sum of 4 quarters · filed 2020-08-06 | ||
| 2019-03-31 | $1.41M 10-Q · filed 2020-05-07 | $2.33M derived: sum of 2 quarters · filed 2020-05-07 | $3.00M derived: sum of 3 quarters · filed 2020-05-07 | $3.67M derived: sum of 4 quarters · filed 2020-05-07 | ||
| 2018-12-31 | $926.36K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $1.59M derived: sum of 2 quarters · filed 2020-03-27 | $2.26M derived: sum of 3 quarters · filed 2020-03-27 | $3.33M 10-K · filed 2020-03-27 | $3.40M 10-K · filed 2019-02-26 | |
| 2018-09-30 | $667.53K 10-Q · filed 2018-11-09 | $1.34M derived: sum of 2 quarters · filed 2019-11-12 | $2.40M 10-Q · filed 2019-11-12 | $2.97M derived: sum of 4 quarters · filed 2019-11-12 | ||
| 2018-06-30 | $667.53K 10-Q · filed 2019-11-12 | $840.00K 10-Q · filed 2018-08-09 | $1.74M 10-Q · filed 2019-08-08 | $2.30M derived: sum of 3 quarters · filed 2019-11-12 | $17.20M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-03-31 | $897.26K 10-Q · filed 2019-05-10 | $1.63M derived: sum of 2 quarters · filed 2019-05-10 | $16.53M derived: sum of 3 quarters · filed 2019-05-10 | $17.13M derived: sum of 4 quarters · filed 2019-05-10 | ||
| 2017-12-31 | $736.80K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $15.63M derived: sum of 2 quarters · filed 2019-02-26 | $16.23M derived: sum of 3 quarters · filed 2019-02-26 | $16.60M 10-K · filed 2019-02-26 | ||
| 2017-09-30 | $14.90M 10-Q · filed 2018-11-09 | $15.49M derived: sum of 2 quarters · filed 2018-11-09 | $15.87M 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | $594.96K 10-Q · filed 2018-08-09 | $968.80K 10-Q · filed 2018-08-09 | ||||
| 2017-03-31 | $373.84K 10-Q · filed 2018-05-11 | |||||
| 2016-12-31 | $1.19M 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |